Cell-penetrating peptides: Strategies for anticancer treatment

Trends in Molecular Medicine

Volumn 21, Issue 9, 2015, Pages 560-570

  Raucher, Drazen ^a   Ryu, Jung Su ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Anticancer; Cell penetrating peptide; Elastin like polypeptide; Tumor targeting

Indexed keywords

ANTINEOPLASTIC AGENT; CELL PENETRATING PEPTIDE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER THERAPY; CELL SPECIFICITY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; HUMAN; HYDROPHOBICITY; HYPERTHERMIA; MICELLE; MOLECULARLY TARGETED THERAPY; NONHUMAN; REVIEW; ANIMAL; EVALUATION STUDY; NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS;

EID: 84940526100     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.06.005     Document Type: Review

References (106)

1. Allen T.M., Cullis P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 2013, 65:36-48.
2. Li Y-P., et al. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J. Control. Release 2001, 71:203-211.
3. Ryu J.S., et al. Penetrating the cell membrane, thermal targeting and novel anticancer drugs: the development of thermally targeted, elastin-like polypeptide cancer therapeutics. Ther. Deliv. 2014, 5:429-445.
4. Figueiredo I.R., et al. Cell-penetrating peptides: A tool for effective delivery in gene-targeted therapies. IUBMB Life 2014, 66:182-194.
5. Sebbage V. Cell-penetrating peptides and their therapeutic applications. Biosci. Horizons 2009, 2:64-72.
6. Fales A.M., et al. Cell-penetrating peptide enhanced intracellular Raman imaging and photodynamic therapy. Mol. Pharm. 2013, 10:2291-2298.
7. Aroui S., et al. Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous TRAIL-induced apoptosis. Apoptosis 2009, 14:1352-1365.
8. Frankel A.D., Pabo C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988, 55:1189-1193.
9. El-Sayed A., et al. Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J. 2009, 11:13-22.
10. Regberg J., et al. Applications of cell-penetrating peptides for tumor targeting and future cancer therapies. Pharmaceuticals (Basel) 2012, 5:991-1007.
11. Dokka S., et al. Cellular delivery of oligonucleotides by synthetic import peptide carrier. Pharm. Res. 1997, 14:1759-1764.
12. Nakayama F., et al. Fibroblast growth factor-12 (FGF12) translocation into intestinal epithelial cells is dependent on a novel cell-penetrating peptide domain: involvement of internalization in the in vivo role of exogenous FGF12. J. Biol. Chem. 2011, 286:25823-25834.
13. Deshayes S., et al. Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. Adv. Drug Deliv. Rev. 2008, 60:537-547.
14. Fernandez-Carneado J., et al. Amphipathic peptides and drug delivery. Biopolymers 2004, 76:196-203.
15. Tian H., et al. RGD targeting hyaluronic acid coating system for PEI-PBLG polycation gene carriers. J. Control. Release 2011, 155:47-53.
16. Elliott G., O'Hare P. Intercellular trafficking of VP22-GFP fusion proteins. Gene Ther. 1999, 6:149-151.
17. Dietrich U., et al. Peptides as drugs: from screening to application. Curr. Pharm. Biotechnol. 2013, 14:501-512.
18. Morris M.C., et al. Cell-penetrating peptides: from molecular mechanisms to therapeutics. Biol. Cell 2008, 100:201-217.
19. Fonseca S.B., et al. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv. Drug Deliv. Rev. 2009, 61:953-964.
20. Richard J.P., et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 2003, 278:585-590.
21. Futaki S., et al. Arginine-rich peptides and their internalization mechanisms. Biochem. Soc. Trans. 2007, 35:784-787.
22. Mayor S., Pagano R.E. Pathways of clathrin-independent endocytosis. Nat. Rev. Mol. Cell Biol. 2007, 8:603-612.
23. El-Andaloussi S., et al. Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochem. J. 2007, 407:285-292.
24. Maler L. Solution NMR studies of cell-penetrating peptides in model membrane systems. Adv. Drug Deliv. Rev. 2013, 65:1002-1011.
25. Prochiantz A. Homeoprotein intercellular transfer, the hidden face of cell-penetrating peptides. Methods Mol. Biol. 2011, 683:249-257.
26. Mor A., et al. Isolation, amino acid sequence, and synthesis of dermaseptin, a novel antimicrobial peptide of amphibian skin. Biochemistry 1991, 30:8824-8830.
27. Marcos J.F., Gandia M. Antimicrobial peptides: to membranes and beyond. Expert Opin. Drug Discov. 2009, 4:659-671.
28. Shai Y. Mode of action of membrane active antimicrobial peptides. Biopolymers 2002, 66:236-248.
29. Bolton S.J., et al. Cellular uptake and spread of the cell-permeable peptide penetratin in adult rat brain. Eur. J. Neurosci. 2000, 12:2847-2855.
30. Lim K.J., et al. A cancer specific cell-penetrating peptide, BR2, for the efficient delivery of an scFv into cancer cells. PLoS ONE 2013, 8:e66084.
31. Svensen N., et al. Peptides for cell-selective drug delivery. Trends Pharmacol. Sci. 2012, 33:186-192.
32. Ruoslahti E., et al. Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 2010, 188:759-768.
33. Tan M., et al. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res. 2006, 66:3764-3772.
34. Salazar M.D.A., Ratnam M. The folate receptor: what does it promise in tissue-targeted therapeutics?. Cancer Metastasis Rev. 2007, 26:141-152.
35. Kunath K., et al. Integrin targeting using RGD-PEI conjugates for in vitro gene transfer. J. Gene Med. 2003, 5:588-599.
36. Wang L., et al. CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. Biomaterials 2012, 33:5107-5114.
37. Aina O.H., et al. Therapeutic cancer targeting peptides. Peptide Sci. 2002, 66:184-199.
38. Endoh T., Ohtsuki T. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv. Drug Deliv. Rev. 2009, 61:704-709.
39. Moktan S., et al. A thermally responsive biopolymer conjugated to an acid-sensitive derivative of paclitaxel stabilizes microtubules, arrests cell cycle, and induces apoptosis. Invest. New Drugs 2012, 30:236-248.
40. Dreher M.R., et al. Evaluation of an elastin-like polypeptide-doxorubicin conjugate for cancer therapy. J. Control. Release 2003, 91:31-43.
41. Leriche G., et al. Cleavable linkers in chemical biology. Bioorg. Med. Chem. 2012, 20:571-582.
42. Alves I.D., et al. A proapoptotic peptide conjugated to penetratin selectively inhibits tumor cell growth. Biochim. Biophys. Acta Biomembranes 2014, 1838:2087-2098.
43. Choi K.Y., et al. Protease-activated drug development. Theranostics 2012, 2:156.
44. Orzechowska E.J., et al. Controlled delivery of BID protein fused with TAT peptide sensitizes cancer cells to apoptosis. BMC Cancer 2014, 14:771.
45. Wang H-X., et al. Matrix metalloproteinase 2-responsive micelle for siRNA delivery. Biomaterials 2014, 35:7622-7634.
46. Biswas S., et al. Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer. Cancer Lett. 2013, 335:191-200.
47. Tiwari P.M., et al. Enhanced intracellular translocation and biodistribution of gold nanoparticles functionalized with a cell-penetrating peptide (VG-21) from vesicular stomatitis virus. Biomaterials 2014, 35:9484-9494.
48. Massodi I., et al. Evaluation of cell penetrating peptides fused to elastin-like polypeptide for drug delivery. J. Control. Release 2005, 108:396-408.
49. Torchilin V.P., et al. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:1972-1977.
50. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
51. Maeda H., et al. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 2009, 71:409-419.
52. Kesharwani P., et al. Dendrimer as nanocarrier for drug delivery. Prog. Polymer Sci. 2014, 39:268-307.
53. Chen F., et al. Theranostic nanoparticles. J. Nucl. Med. 2014, 55:1919-1922.
54. Rhyner M.N., et al. Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging. Nanomedicine 2006, 1:209-217.
55. Li K., et al. Photostable fluorescent organic dots with aggregation-induced emission (AIE dots) for noninvasive long-term cell tracing. Sci. Rep. 2013, 3:1150.
56. Shin M.C., et al. Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy. J. Control. Release 2014, 194:197-210.
57. Parker N., et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem. 2005, 338:284-293.
58. Garin-Chesa P., et al. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am. J. Pathol. 1993, 142:557.
59. Kang M.J., et al. Folic acid-tethered Pep-1 peptide-conjugated liposomal nanocarrier for enhanced intracellular drug delivery to cancer cells: conformational characterization and in vitro cellular uptake evaluation. Int. J. Nanomedicine 2013, 8:1155.
60. Barczyk M., et al. Integrins. Cell Tissue Res. 2010, 339:269-280.
61. Liu Y., et al. Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting. Biomaterials 2014, 35:4835-4847.
62. Ryu J.S., Raucher D. Elastin-like polypeptide for improved drug delivery for anticancer therapy: preclinical studies and future applications. Expert Opin. Drug Deliv. 2014, 1-15.
63. Bidwell G.L., Raucher D. Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. Mol. Cancer Ther. 2005, 4:1076-1085.
64. Ryu J.S., Raucher D. Elastin-like polypeptides: the influence of its molecular weight on local hyperthermia-induced tumor accumulation. Eur. J. Pharm. Biopharm. 2014, 88:382-389.
65. Ryu J.S., Raucher D. Anti-tumor efficacy of a therapeutic peptide based on thermo-responsive elastin-like polypeptide in combination with gemcitabine. Cancer Lett. 2014, 348:177-184.
66. Bidwell G.L., et al. A thermally targeted c-Myc inhibitory polypeptide inhibits breast tumor growth. Cancer Lett. 2012, 319:136-143.
67. Massodi I., et al. Inhibition of ovarian cancer cell proliferation by a cell cycle inhibitory peptide fused to a thermally responsive polypeptide carrier. Int. J. Cancer 2010, 126:533-544.
68. Cantini L., et al. Fusogenic-oligoarginine peptide-mediated delivery of siRNAs targeting the CIP2A oncogene into oral cancer cells. PLoS ONE 2013, 8:e73348.
69. Yang Y., et al. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy. Biomaterials 2014, 35:4368-4381.
70. Savariar E.N., et al. Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides. Cancer Res. 2013, 73:855-864.
71. Crisp J.L., et al. Dual targeting of integrin αvβ3 and matrix metalloproteinase-2 for optical imaging of tumors and chemotherapeutic delivery. Mol. Cancer Ther. 2014, 13:1514-1525.
72. Tannock I.F., Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989, 49:4373-4384.
73. Kale A.A., Torchilin V.P. Environment-responsive multifunctional liposomes. Liposomes-Methods and Protocols, Volume 1: Pharmaceutical Nanocarriers 2010, 213-242. Springer. V. Weissig (Ed.).
74. Sawant R., et al. 'SMART' drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug. Chem. 2006, 17:943-949.
75. Klein T., Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011, 41:271-290.
76. Roy R., et al. Matrix metalloproteinases as novel biomarker s and potential therapeutic targets in human cancer. J. Clin. Oncol. 2009, 27:5287-5297.
77. Yu X., Han Z. Matrix metalloproteinases in bone marrow: roles of gelatinases in physiological hematopoiesis and hematopoietic malignancies. Histol. Histopathol. 2006, 21:519-531.
78. Liu Z., et al. Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment. Nat. Commun. 2014, 5:4280.
79. Bechara C., Sagan S. Cell-penetrating peptides: 20 years later, where do we stand?. FEBS Lett. 2013, 587:1693-1702.
80. Lebleu B., et al. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv. Drug Deliv. Rev. 2008, 60:517-529.
81. Brandt F., et al. Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines. Dermatol. Surg. 2010, 36(Suppl. 4):2111-2118.
82. Lopes L.B., et al. Cell permeant peptide analogues of the small heat shock protein, HSP20, reduce TGF-beta1-induced CTGF expression in keloid fibroblasts. J. Invest. Dermatol. 2009, 129:590-598.
83. Cousins M.J., et al. The safety and efficacy of KAI-1678- an inhibitor of epsilon protein kinase C (epsilonPKC)-versus lidocaine and placebo for the treatment of postherpetic neuralgia: a crossover study design. Pain Med. 2013, 14:533-540.
84. Miyaji Y., et al. Distribution of KAI-9803, a novel delta-protein kinase C inhibitor, after intravenous administration to rats. Drug Metab. Dispos. 2011, 39:1946-1953.
85. Warso M.A., et al. A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. Br. J. Cancer 2013, 108:1061-1070.
86. Mehta R.R., et al. A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt. Angiogenesis 2011, 14:355-369.
87. Coriat R., et al. First-in-human phase I and pharmacokinetic study of DTS-108 in patients with advanced carcinomas. J. Clin. Oncol. 2012, 30(Suppl.):2557.
88. Tanaka K., et al. Cytoplasm-responsive nanocarriers conjugated with a functional cell-penetrating peptide for systemic siRNA delivery. Int. J. Pharm. 2013, 455:40-47.
89. Fang B., et al. A novel cell-penetrating peptide TAT-A1 delivers siRNA into tumor cells selectively. Biochimie 2013, 95:251-257.
90. Gehrmann M., et al. Tumor imaging and targeting potential of an Hsp70-derived 14-mer peptide. PLoS ONE 2014, 9:e105344.
91. Suh J.S., et al. Simultaneous imaging and restoration of cell function using cell permeable peptide probe. Biomaterials 2014, 35:6287-6298.
92. Park H., et al. Cell penetration and cell-selective drug delivery using α-helix peptides conjugated with gold nanoparticles. Biomaterials 2013, 34:4872-4879.
93. Kim S.M., et al. Enhanced cellular uptake of a TAT-conjugated peptide inhibitor targeting the polo-box domain of polo-like kinase 1. Amino Acids 2014, 46:2595-2603.
94. Barras D., et al. A WXW motif is required for the anticancer activity of the TAT-RasGAP317-326 peptide. J. Biol. Chem. 2014, 289:23701-23711.
95. Tints K., et al. LXXLL peptide converts transportan 10 to a potent inducer of apoptosis in breast cancer cells. Int. J. Mol. Sci. 2014, 15:5680-5698.
96. Kim D., et al. A specific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling. Cancer Res. 2014, 74:2144-2151.
97. Prezma T., et al. VDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia. Cell Death Dis. 2013, 4:e809.
98. Kuroda Y., et al. Oligopeptides derived from autophosphorylation sites of EGF receptor suppress EGF-stimulated responses in human lung carcinoma A549 cells. Eur. J. Pharmacol. 2013, 698:87-94.
99. Zhao B., et al. TAT-mediated gp96 transduction to APCs enhances gp96-induced antiviral and antitumor T cell responses. Vaccine 2013, 31:545-552.
100. Bidwell G.L., et al. Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. Biochem. Pharmacol. 2007, 73:620-631.
101. Bidwell G.L., et al. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Invest. New Drugs 2007, 25:313-326.
102. Bidwell G.L., Raucher D. Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc. Biochem. Pharmacol. 2006, 71:248-256.
103. Massodi I., et al. Inhibition of ovarian cancer cell metastasis by a fusion polypeptide Tat-ELP. Clin. Exp. Metastasis 2009, 26:251-260.
104. Massodi I., et al. Application of thermally responsive elastin-like polypeptide fused to a lactoferrin-derived peptide for treatment of pancreatic cancer. Molecules 2009, 14:1999-2015.
105. Moktan S., Raucher D. Anticancer activity of proapoptotic peptides is highly improved by thermal targeting using elastin-like polypeptides. Int. J. Pept. Res. Ther. 2012, 18:227-237.
106. Bidwell G.L., et al. A thermally targeted peptide inhibitor of symmetrical dimethylation inhibits cancer-cell proliferation. Peptides 2010, 31:834-841.